Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.

Zhang H, Zhang X, Hu C, Lu W

Kidney & blood pressure research8 Jun 2012Cited by 69 (Europe PMC)

PMID22687869DOI10.1159/000337929PepBankPUB-22687869

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with diabetes and microalbuminuria, exenatide lowered urinary albumin compared with glimepiride.
In plain wordsIn patients with diabetes and microalbuminuria, exenatide lowered urine albumin more than glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
Decrease24-hour urinary albumin
Study
n = 31
Comparator
glimepiride
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-β(1) and type IV collagen in group Exe were significantly lower than those of group Glm (p < 0.01), while glycemic control had no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks.
Report a problemFND-2268786901
02HumanRandomized controlled trialEfficacy outcome
In patients with diabetes and microalbuminuria, exenatide lowered urinary TGF-beta1 compared with glimepiride.
In plain wordsIn patients with diabetes and microalbuminuria, exenatide lowered urine TGF-beta1 more than glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUrinary TGF-beta1
Study
n = 31
Comparator
glimepiride
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-β(1) and type IV collagen in group Exe were significantly lower than those of group Glm (p < 0.01), while glycemic control had no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks.
Report a problemFND-2268786902
03HumanRandomized controlled trialEfficacy outcome
In patients with diabetes and microalbuminuria, exenatide lowered urinary type IV collagen compared with glimepiride.
In plain wordsIn patients with diabetes and microalbuminuria, exenatide lowered urine type IV collagen more than glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUrinary type IV collagen
Study
n = 31
Comparator
glimepiride
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-β(1) and type IV collagen in group Exe were significantly lower than those of group Glm (p < 0.01), while glycemic control had no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks.
Report a problemFND-2268786903
04HumanRandomized controlled trialEfficacy outcome
In patients with diabetes and microalbuminuria, glycemic control did not differ significantly between exenatide and glimepiride.
In plain wordsIn patients with diabetes and microalbuminuria, blood sugar control did not differ significantly between exenatide and glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGlycemic control
Study
n = 31
Comparator
glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-β(1) and type IV collagen in group Exe were significantly lower than those of group Glm (p < 0.01), while glycemic control had no statistical difference between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks.
Report a problemFND-2268786904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02690883

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

Nanfang Hospital, Southern Medical Universityn = 928 Apr 2016 to 30 Dec 2019

Diabetic Nephropathies

Trial page ClinicalTrials.govUpdated 9 Mar 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.